Aduhelm Approved for Alzheimer's Disease

Aduhelm (aducanumab), developed by Biogen and Eisai, was approved by the U.S. Food and Drug Administration in June 2021, making it the first disease-modifying therapy for the treatment of Alzheimer’s disease. It is designed to reduce the number of amyloid plaques present in the brain, potentially slowing neurodegeneration and disease progression. Learn more about this therapy and its path to approval below.

Learn more
Aduhelm approved

FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy

For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, also known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients. With…

Read more
multigenerational households | Alzheimer's News Today | Main graphic for column titled

Debunking Myths About Alzheimer’s Disease

There’s a lot unknown about Alzheimer’s disease, and many myths surround the mind-altering disease. It’s necessary to separate fact from fiction. As misnomers are addressed, it removes some of the stigmas attached to Alzheimer’s. Because knowledge is power, it…